Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNα

被引:70
作者
Brender, C
Lovato, P
Sommer, VH
Woetmann, A
Mathiesen, AM
Geisler, C
Wasik, M
Odum, N
机构
[1] Univ Copenhagen, Inst Med Microbiol & Immunol, Inst Mol Biol, DK-2200 Copenhagen N, Denmark
[2] Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
SOCS-3; CTCL; tumour suppressor;
D O I
10.1038/sj.leu.2403610
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Signal transducer and activator of transcription (Stat) 3 is constitutively activated in cutaneous T-cell lymphoma ( CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is transiently expressed following cytokine stimulation and functions as a negative feedback inhibitor of the Stat3-activating kinases. Here, we attempt to resolve the apparent paradox of a simultaneous SOCS-3 expression and Stat3 activation in the same cells. We show that ( i)SOCS-3 expression in tumour cells is equal to or higher than in cytokine-stimulated nonmalignant T cells, (ii) SOCS-3 is not mutated in CTCL, (iii) overexpression of SOCS-3 blocks IFNalpha-mediated growth inhibition without affecting Stat3 activation, growth, and apoptosis, and (iv) inhibition of SOCS-3 by a dominant negative Stat3 (Stat3D) increases the IFNalpha-mediated growth inhibition. Taken together, these data show that SOCS-3 does not inhibit Stat3 activation, growth, and survival in CTCL. In contrast, SOCS3 protects tumour cells against growth inhibition by IFNalpha. Unlike SOCS-1, SOCS-3 is therefore not a tumour suppressor but rather a protector of tumour cells.
引用
收藏
页码:209 / 213
页数:5
相关论文
共 37 条
[1]   Suppressors of cytokine signalling (SOCS) in the immune system [J].
Alexander, WS .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (06) :410-416
[2]   SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine [J].
Alexander, WS ;
Starr, R ;
Fenner, JE ;
Scott, GL ;
Handman, E ;
Sprigg, NS ;
Corbin, JE ;
Cornish, AL ;
Darwiche, R ;
Owczarek, CM ;
Kay, TWH ;
Nicola, NA ;
Hertzog, PJ ;
Metcalf, D ;
Hilton, DJ .
CELL, 1999, 98 (05) :597-608
[3]   Interferon-alpha induces transient suppressors of cytokine signalling expression in human T cells [J].
Brender, C ;
Nielsen, M ;
Röpke, C ;
Nissen, MH ;
Svejgaard, A ;
Billestrup, N ;
Geisler, C ;
Odum, N .
EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, 2001, 18 (02) :80-85
[4]   STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma [J].
Brender, C ;
Nielsen, M ;
Kaltoft, K ;
Mikkelsen, G ;
Zhang, Q ;
Wasik, M ;
Billestrup, N ;
Odum, N .
BLOOD, 2001, 97 (04) :1056-1062
[5]   Stat3 as an oncogene [J].
Bromberg, JF ;
Wrzeszczynska, MH ;
Devgan, G ;
Zhao, YX ;
Pestell, RG ;
Albanese, C ;
Darnell, JE .
CELL, 1999, 98 (03) :295-303
[6]   Stat3 activation is required for cellular transformation by v-src [J].
Bromberg, JF ;
Horvath, CM ;
Besser, D ;
Lathem, WW ;
Darnell, JE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (05) :2553-2558
[7]   Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras [J].
Cacalano, NA ;
Sanden, D ;
Johnston, JA .
NATURE CELL BIOLOGY, 2001, 3 (05) :460-465
[8]   SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia [J].
Chen, CY ;
Tsay, W ;
Tang, JL ;
Shen, HL ;
Lin, SW ;
Huang, SY ;
Yao, M ;
Chen, YC ;
Shen, MC ;
Wang, CH ;
Tien, HF .
GENES CHROMOSOMES & CANCER, 2003, 37 (03) :300-305
[9]  
Cohney SJ, 1999, MOL CELL BIOL, V19, P4980
[10]   STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells [J].
de Groot, RP ;
Raaijmakers, JAM ;
Lammers, JWJ ;
Jove, R ;
Koenderman, L .
BLOOD, 1999, 94 (03) :1108-1112